CDEK
← All drugs Report issue

lincomycin

Trade name: lincocin

Small moleculeapproved

Approved

Dec 29, 1964

Lincomycin (LINCOCIN®) is an antibiotic produced by Streptomyces lincolnensis (Streptomycetaceae family). It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. Lincomycin (LINCOCIN®) inhibits protein synthesis in susceptible bacteria by binding to the 50S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible microorganisms. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 12 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2009 (NCT01058824)

Timeline

1960s

  1. Dec 29, 1964

    Pharmacia & Upjohn — Earliest FDA Approval

  2. Dec 29, 1964

    Pharmacia & Upjohn — NDA Secondary Org

  3. Dec 29, 1964

    Pfizer — Marketing Organization

  4. Dec 29, 1964

    Pharmacia & Upjohn — NDA Organization

  5. Dec 29, 1964

    Pfizer — NDA Secondary Org

1990s

  1. Apr 16, 1991

    Watson Pharmaceuticals — Marketing Organization

2000s

  1. Jan 1, 2009

    Pfizer — Earliest Phase 1 Sponsor(trial)

2010s

  1. Jun 4, 2015

    X Gen Pharmaceuticals — Marketing Organization

2020s

  1. Mar 12, 2021

    Athenex, Inc. — Marketing Organization

  2. Mar 12, 2021

    Praxgen Pharma — Marketing Organization

  3. Mar 12, 2021

    Geneyork Pharmaceuticals — Marketing Organization

  4. Nov 8, 2021

    Micro Labs Ltd India — Marketing Organization

  5. Sep 26, 2022

    Gland Pharma Ltd — Marketing Organization

  6. Sep 26, 2022

    Fosun — Marketing Organization

  7. Dec 21, 2022

    Hainan Poly Pharm — Marketing Organization

  8. Dec 21, 2022

    SLATE RUN PHARMA — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 29, 1964

Chemistry & pharmacology

Loading structure…

SMILES

CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@@H](C)O)N(C)C1.Cl.O
Mol. weight
461.02 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • cillimycin
  • jiemycin
  • lcm
  • lcm
  • lincocin
  • lincocin
  • lincocin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin
  • lincomycin a
  • lincomycine
  • lincomycine
  • lincomycin hcl
  • lincomycin hcl
  • lincomycin hcl
  • lincomycin hydrochloride
  • lincomycin hydrochloride
  • lincomycin hydrochloride
  • lincomycin hydrochloride
  • medoglycine
  • u-10149
  • u-10149

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01058824Phase 1Apr 1, 2009Pfizer
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit1112009
1 organizations
Page 1 / 1

Marketing (15)

OrganizationOrg typeRelationshipDate
Athenex, Inc.For profitMKTGMar 12, 2021
FosunFor profitMKTGSep 26, 2022
Geneyork PharmaceuticalsFor profitMKTGMar 12, 2021
Gland Pharma LtdFor profitMKTGSep 26, 2022
Hainan Poly PharmFor profitMKTGDec 21, 2022
Micro Labs Ltd IndiaFor profitMKTGNov 8, 2021
PfizerFor profitMKTGDec 29, 1964
PfizerFor profitNDA2Dec 29, 1964
Pharmacia & UpjohnFor profitNDA2Dec 29, 1964
Pharmacia & UpjohnFor profitNDADec 29, 1964
Praxgen PharmaFor profitMKTGMar 12, 2021
SLATE RUN PHARMAFor profitMKTGDec 21, 2022
Watson PharmaceuticalsFor profitMKTGApr 16, 1991
X Gen PharmaceuticalsFor profitMKTGJun 4, 2015
X Gen PharmaceuticalsFor profitSYNJun 4, 2015